Poseida Therapeutics prostate cancer drug trial halted after patient dies

/ / News

Poseida Therapeutics Inc. shares were halted in the extended session Monday as the biotech drug maker announced a safety trial for a prostate cancer drug had been halted because of a patient death. Poseida shares closed the regular session down 0.8% at $13.00. In a Securities and Exchange Commission filing, Poseida said the Food and Drug Administration paused the company’s Phase 1 trial for its prostate cancer treatment dubbed P-PSMA-101 to investigate the death of a patient enrolled in the study. The clinical investigator on the study said the death was “possibly” related to the treatment. Poseida launched its initial public offering in July with shares priced at $16 a piece.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.